


UChicago Grand Rounds Program: New Developments in the Management of Hematological Malignancies & Transplant February 7, 2013 Activity Eval.

1. Please identify yourself:

		Response Percent	Response Count
MD/DO		100.0%	7
Nurse		0.0%	0
Fellow/Resident		0.0%	0
answered question			7
skipped question			1

2. Prior to participating in this activity, please rate your ability to: (5=Completely, 1=Not at all)

	5	4	3	2	1	Rating Average	Rating Count
Transplantation: Understand evolving indications for transplantation in non-Hodgkin's lymphomas & chronic lymphocytic leukemia.	28.6% (2)	14.3% (1)	57.1% (4)	0.0% (0)	0.0% (0)	3.71	7
Multiple Myeloma: Understand the evolving strategy of initial management of multiple myeloma; New developments & drugs for treatment of relapsed & refractory myeloma	33.3% (2)	16.7% (1)	50.0% (3)	0.0% (0)	0.0% (0)	3.83	6
Lymphoma: Understand the treatment approaches for newly diagnosed non-Hodgkin's lymphomas; New agents on the horizon for non-Hodgkin's lymphomas	28.6% (2)	57.1% (4)	14.3% (1)	0.0% (0)	0.0% (0)	4.14	7
Leukemia: Understand new insights from the myeloid neoplasms: How biology is revealing new opportunities for treatment; Progress in Lymphoid Malignancies: Hot off the press	28.6% (2)	14.3% (1)	42.9% (3)	14.3% (1)	0.0% (0)	3.57	7
answered question							7
skipped question							1

3. After to participating in this activity, please rate your ability to: (5=Completely, 1=Not at all)

	5	4	3	2	1	Rating Average	Rating Count
Transplantation: Understand Evolving indications for transplantation in non-Hodgkin's lymphomas & chronic lymphocytic leukemia.	71.4% (5)	14.3% (1)	14.3% (1)	0.0% (0)	0.0% (0)	4.57	7
Multiple Myeloma: Understand the evolving strategy of initial management of multiple myeloma; New developments & drugs for treatment of relapsed & refractory myeloma	66.7% (4)	33.3% (2)	0.0% (0)	0.0% (0)	0.0% (0)	4.67	6
Lymphoma: Understand the treatment approaches for newly diagnosed non-Hodgkin's lymphomas; New agents on the horizon for non-Hodgkin's lymphomas	57.1% (4)	28.6% (2)	14.3% (1)	0.0% (0)	0.0% (0)	4.43	7
Leukemia: Understand new insights from the myeloid neoplasms: How biology is revealing new opportunities for treatment; Progress in Lymphoid Malignancies: Hot off the press	71.4% (5)	0.0% (0)	28.6% (2)	0.0% (0)	0.0% (0)	4.43	7
answered question							7
skipped question							1









4. Did this activity:

	5	4	3	2	1	Rating Average	Rating Count
Address the competencies/attributes relevant to your specialty?	75.0% (6)	25.0% (2)	0.0% (0)	0.0% (0)	0.0% (0)	4.75	8
Equip you with information to overcome barriers to treatment?	37.5% (3)	37.5% (3)	12.5% (1)	12.5% (1)	0.0% (0)	4.00	8
Increase your competence, skills, and/or performance in providing improved patient care?	50.0% (4)	37.5% (3)	12.5% (1)	0.0% (0)	0.0% (0)	4.38	8
Present the material in a format appropriate to the topic?	62.5% (5)	37.5% (3)	0.0% (0)	0.0% (0)	0.0% (0)	4.63	8
answered question							8
skipped question							0






5. After participating in this activity, will you make any changes in your practice? (Please explain).

	Response Count
	4
answered question	4
skipped question	4






6. These are the barriers I face in my current practice setting that may impact patient outcomes:

		Response Percent	Response Count
Lack of evidence-based guidelines;		0.0%	0
Lack of applicable guidelines for my current practice/patients;		0.0%	0
Lack of time;		100.0%	3
Organizational/institutional;		0.0%	0
Insurance/financial;		66.7%	2
Patient adherence/compliance;		66.7%	2
Treatment-related adverse events;		33.3%	1
Other (Please provide below).		0.0%	0
		.	0
answered question			3
skipped question			5

7. How much of the content presented at this meeting was new to you?

		Response Percent	Response Count
0-20%		0.0%	0
21-40%		57.1%	4
41-60%		14.3%	1
61-80%		28.6%	2
81-100%		0.0%	0
answered question			7
skipped question			1


8. How many years have you been in practice?

		Response Percent	Response Count
0-5 years		14.3%	1
6-15 years		14.3%	1
16-25 years		42.9%	3
26-30 years		14.3%	1
31+ years		14.3%	1
answered question			7
skipped question			1

9. Please rate the overall lecture: (5=Excellent, 1=Poor)

	5	4	3	2	1	Rating Average	Rating Count
Educational Content	85.7% (6)	14.3% (1)	0.0% (0)	0.0% (0)	0.0% (0)	4.86	7
Speaker Selection	85.7% (6)	14.3% (1)	0.0% (0)	0.0% (0)	0.0% (0)	4.86	7
answered question							7
skipped question							1

10. Did any of the presentations contain pharmaceutical company or medical device manufacturer bias?

		Response Percent	Response Count
Yes		0.0%	0
No		100.0%	7
Comments(please be as specific as possible):			0
answered question			7
skipped question			1

11. List future CME topics that would be of value to you, and please be specific.

	Response Count
	3
answered question	3
skipped question	5

12. General Comments:

	Response Count
	4
answered question	4
skipped question	4

Page 1, Q5. After participating in this activity, will you make any changes in your practice? (Please explain).

1	Refer appropriate patients for trials with new/ (illegible)	Jul 12, 2013 3:17 PM
2	I will consider earlier referral for studies etc (Mission accomplished.	Jul 12, 2013 3:10 PM
3	Use more benodi (illegible) + Revland!	Jul 12, 2013 3:02 PM
4	Higher likelihood to send/refer patients to UCH for trial	Jul 12, 2013 3:00 PM

Page 2, Q5. List future CME topics that would be of value to you, and please be specific.

1	Review coourses (illegible) Asco, San Antonio (illegible) Conference	Jul 12, 2013 3:17 PM
2	Challenging cases , AJW Review	Jul 12, 2013 3:14 PM
3	This format would lend itself to topics in new developments in Hemo+Onc	Jul 12, 2013 3:12 PM

Page 2, Q7. General Comments:

1	Prefer longer sessions on Saturdays, rather than weekday evening. Provide copies of slides projected.	Jul 12, 2013 3:17 PM
2	Please come again (on a nicer day) This is a very digestible way of learning, hearing + thinking about (illegible) type of information.	Jul 12, 2013 3:12 PM
3	Very good.	Jul 12, 2013 2:58 PM
4	Good speakers.	Jul 12, 2013 2:58 PM